Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

News provided by Eli Lilly and Company Jun 17, 2025, 6:45 AM ET Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked ...

Eli Lilly (NYSE:LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B, the Financial Times reported. The drugmaker's acquisition offer ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in ...

News provided by Eli Lilly and Company Jun 17, 2025, 6:45 AM ET Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked ...

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk By Eli Lilly and Company, Verve Therapeutics, Inc. Jun 17, 2025 Updated Jun 17, 2025 1 of 2 ...

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 News provided by Beam Therapeutics Oct 31, 2023 ...